Skip to content
2000
Volume 15, Issue 8
  • ISSN: 2210-3155
  • E-ISSN: 2210-3163

Abstract

Background

Psoriasis is an inflammatory skin disease characterized by hyper-proliferating epidermal membrane and accumulation of dermal inflammatory cells. A profound understanding of mechanistic studies has revealed the potential role of TNF-α and IL-17a in disease pathogenesis.

Objective

The study aims to evaluate the inhibitory potential of octyl gallate on IL-17a through analysis and validate its anti-inflammatory effects against oxidative stress and proinflammatory cytokines . The objective of the study is to evaluate the potential of octyl gallate for the treatment of psoriasis by targeting inflammatory mediators using and approaches.

Methods

The anti-oxidant potential of octyl gallate was evaluated through chemiluminescence and the Griess method. Cytotoxicity was evaluated MTT assay. TNF-α levels were quantified through ELISA. Mechanistic studies were performed to recognize the inhibition of strong inflammatory mediators, such as TNF-α, IL-1β, IL-6, NCF-1, and NF-κB through gene expression analysis. Molecular docking was performed to study the underlying binding pattern of gallate inhibitor with IL-17a.

Results

Octyl gallate potently inhibited TNF-α, reactive oxygen, and nitrogen species while significantly reducing the expression of inflammatory genes. The docking analysis revealed that octyl gallate resides well in the binding pocket of IL17a. The physicochemical properties of gallate resulted in a good ADME profile.

Conclusion

Octyl gallate revealed a significant antioxidant potential and downregulation of inflammatory genes principally involved in psoriasis. A new inhibitory target IL-17a of octyl gallate has been identified that, together with TNF-α, develops a feed-forward state in disease pathogenesis. This study signifies the potential of octyl gallate to be a prospective lead molecule for the treatment of psoriasis.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/npj/10.2174/2210315513666230309141639
2025-05-12
2025-09-09

  • From This Site

    /content/journals/npj/10.2174/2210315513666230309141639
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BoehnckeW.H. SchönM.P. Psoriasis.Lancet2015386999798399410.1016/S0140‑6736(14)61909‑7 26025581
     [Google Scholar]
  2. MichalekI.M. LoringB. JohnS.M. A systematic review of worldwide epidemiology of psoriasis.J. Eur. Acad. Dermatol. Venereol.201731220521210.1111/jdv.13854 27573025
     [Google Scholar]
  3. ItoT. TakahashiH. KawadaA. IizukaH. NakagawaH. Japanese Society For Psoriasis Research. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research.J. Dermatol.201845329330110.1111/1346‑8138.14105 29115687
     [Google Scholar]
  4. OgawaE. OkuyamaR. SekiT. KobayashiA. OisoN. MutoM. NakagawaH. KawadaA. Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture.Japan. J. Dermatol.201845331431710.1111/1346‑8138.14101 29047148
     [Google Scholar]
  5. IchiyamaS. ItoM. FunasakaY. AbeM. NishidaE. MuramatsuS. NishiharaH. KatoH. MoritaA. ImafukuS. SaekiH. Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities.J. Dermatol.201845672773110.1111/1346‑8138.14225 29356075
     [Google Scholar]
  6. SouzaC.S. de CastroC.C.S. CarneiroF.R.O. PintoJ.M.N. FabricioL.H.Z. Azulay-AbulafiaL. RomitiR. CestariT.F. SuzukiC.E. BiegunP.M. GuedesL.S. OyafusoL.K.M. Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence.J. Dermatol.201946131010.1111/1346‑8138.14706 30474868
     [Google Scholar]
  7. GriffithsC.E.M. BarkerJ.N.W.N. Pathogenesis and clinical features of psoriasis.Lancet2007370958326327110.1016/S0140‑6736(07)61128‑3 17658397
     [Google Scholar]
  8. SanchezD.P. Sonthalia, S. Koebner phenomenon,2020
     [Google Scholar]
  9. WeissG. ShemerA. TrauH. The Koebner phenomenon: review of the literature.J. Eur. Acad. Dermatol. Venereol.200216324124810.1046/j.1473‑2165.2002.00406.x 12195563
     [Google Scholar]
  10. DaiY.X. WangS.C. ChouY.J. ChangY.T. ChenT.J. LiC.P. WuC.Y. Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study.J. Am. Acad. Dermatol.201980372773410.1016/j.jaad.2018.11.015 30528570
     [Google Scholar]
  11. KamiyaK. KishimotoM. SugaiJ. KomineM. OhtsukiM. Risk factors for the development of psoriasis.Int. J. Mol. Sci.20192018434710.3390/ijms20184347 31491865
     [Google Scholar]
  12. O’RiellyD.D. JaniM. RahmanP. ElderJ.T. The genetics of psoriasis and psoriatic arthritis.J. Rheumatol.201995465010.3899/jrheum.190119 31154404
     [Google Scholar]
  13. ElderJ.T. Expanded genome-wide association study meta-analysis of psoriasis expands the catalog of common psoriasis-associated variants.J. Investig. Dermatol. Symp. Proc.2018192S77S7810.1016/j.jisp.2018.09.005 30471756
     [Google Scholar]
  14. PleńkowskaJ. Gabig-CimińskaM. MozolewskiP. Oxidative stress as an important contributor to the pathogenesis of psoriasis.Int. J. Mol. Sci.20202117620610.3390/ijms21176206 32867343
     [Google Scholar]
  15. LaiY. DongC. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases.Int. Immunol.201628418118810.1093/intimm/dxv063 26545932
     [Google Scholar]
  16. LowesM.A. BowcockA.M. KruegerJ.G. Pathogenesis and therapy of psoriasis.Nature2007445713086687310.1038/nature05663 17314973
     [Google Scholar]
  17. LowesM.A. Suárez-FariñasM. KruegerJ.G. Immunology of Psoriasis.Annu. Rev. Immunol.201432122725510.1146/annurev‑immunol‑032713‑120225 24655295
     [Google Scholar]
  18. ChiricozziA. Guttman-YasskyE. Suárez-FariñasM. NogralesK.E. TianS. CardinaleI. ChimentiS. KruegerJ.G. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.J. Invest. Dermatol.2011131367768710.1038/jid.2010.340 21085185
     [Google Scholar]
  19. MartinD.A. TowneJ.E. KricorianG. KlekotkaP. GudjonssonJ.E. KruegerJ.G. RussellC.B. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.J. Invest. Dermatol.20131331172610.1038/jid.2012.194 22673731
     [Google Scholar]
  20. MarinoniB. CeribelliA. MassarottiM.S. SelmiC. The Th17 axis in psoriatic disease: Pathogenetic and therapeutic implications.Auto Immun. Highlights20145191910.1007/s13317‑013‑0057‑4 26000152
     [Google Scholar]
  21. ChiricozziA. Suárez-FariñasM. Fuentes-DuculanJ. CuetoI. LiK. TianS. BrodmerkelC. KruegerJ.G. Increased expression of interleukin‐17 pathway genes in nonlesional skin of moderate‐to‐severe psoriasis vulgaris.Br. J. Dermatol.2016174113614510.1111/bjd.14034 26189551
     [Google Scholar]
  22. WangC.Q.F. Suárez-FariñasM. NogralesK.E. MimosoC.A. ShromD. DowE.R. HeffernanM.P. HoffmanR.W. KruegerJ.G. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.J. Invest. Dermatol.2014134122990299310.1038/jid.2014.268 24999591
     [Google Scholar]
  23. KirkhamB.W. KavanaughA. ReichK. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.Immunology2014141213314210.1111/imm.12142 23819583
     [Google Scholar]
  24. KagamiS. RizzoH.L. LeeJ.J. KoguchiY. BlauveltA. Circulating Th17, Th22, and Th1 cells are increased in psoriasis.J. Invest. Dermatol.201013051373138310.1038/jid.2009.399 20032993
     [Google Scholar]
  25. SchülerR. BrandA. KlebowS. WildJ. VerasF.P. UllmannE. RoohaniS. KolbingerF. KossmannS. WohnC. DaiberA. MünzelT. WenzelP. WaismanA. ClausenB.E. KarbachS. Antagonization of IL-17A attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis.J. Invest. Dermatol.2019139363864710.1016/j.jid.2018.09.021 30367871
     [Google Scholar]
  26. MoosS. MohebianyA.N. WaismanA. KurschusF.C. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes.J. Invest. Dermatol.201913951110111710.1016/j.jid.2019.01.006 30684554
     [Google Scholar]
  27. MabuchiT. TakekoshiT. HwangS.T. Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis.J. Immunol.2011187105026503110.4049/jimmunol.1101817 21984702
     [Google Scholar]
  28. MabuchiT. SinghT.P. TakekoshiT. JiaG. WuX. KaoM.C. WeissI. FarberJ.M. HwangS.T. CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-induced model of psoriasiform dermatitis.J. Invest. Dermatol.2013133116417110.1038/jid.2012.260 22895364
     [Google Scholar]
  29. KruegerJ.G. FretzinS. Suárez-FariñasM. HaslettP.A. PhippsK.M. CameronG.S. HoffmanR.W. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.J. Allergy Clin. Immunol.20121301145154
     [Google Scholar]
  30. SuY. HuangJ. ZhaoX. LuH. WangW. YangX.O. ShiY. WangX. LaiY. DongC. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation.Sci. Immunol.2019436eaau965710.1126/sciimmunol.aau9657 31175175
     [Google Scholar]
  31. SønderS.U. SaretS. TangW. SturdevantD.E. PorcellaS.F. SiebenlistU. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms.J. Biol. Chem.201128615128811289010.1074/jbc.M110.199547 21335551
     [Google Scholar]
  32. BaeH.C. JeongS.H. RIP4 upregulates CCL20 expression through STAT3 signalling in cultured keratinocytes.Exp. Dermatol.2018271011261133
     [Google Scholar]
  33. Kennedy-CrispinM. BillickE. MitsuiH. GulatiN. FujitaH. GilleaudeauP. Sullivan-WhalenM. Johnson-HuangL.M. Suárez-FariñasM. KruegerJ.G. Human keratinocytes’ response to injury upregulates CCL20 and other genes linking innate and adaptive immunity.J. Invest. Dermatol.2012132110511310.1038/jid.2011.262 21881590
     [Google Scholar]
  34. RussoC. PolosaR. TNF-α as a promising therapeutic target in chronic asthma: A lesson from rheumatoid arthritis.Clin. Sci.2005109213514210.1042/CS20050038 16033328
     [Google Scholar]
  35. AggarwalB.B. ShishodiaS. TakadaY. Jackson-BernitsasD. AhnK.S. SethiG. IchikawaH. TNF blockade: an inflammatory issue.Ernst Schering Res. Found. Workshop20065616118610.1007/3‑540‑37673‑9_10
     [Google Scholar]
  36. FurueM. FurueK. TsujiG. NakaharaT. Interleukin-17A and keratinocytes in psoriasis.Int. J. Mol. Sci.2020214127510.3390/ijms21041275 32070069
     [Google Scholar]
  37. HelfandS.L. WerkmeisterJ. RoderJ.C. Chemiluminescence response of human natural killer cells. I. The relationship between target cell binding, chemiluminescence, and cytolysis.J. Exp. Med.1982156249250510.1084/jem.156.2.492 6178787
     [Google Scholar]
  38. HeldP. An introduction to reactive oxygen species.Tech Resources-App Guides201280259
     [Google Scholar]
  39. MosmannT. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays.J. Immunol. Methods1983651-2556310.1016/0022‑1759(83)90303‑4 6606682
     [Google Scholar]
  40. LiuS. DakinL.A. XingL. WithkaJ.M. SahasrabudheP.V. LiW. BankerM.E. BalboP. ShankerS. ChrunykB.A. GuoZ. ChenJ.M. YoungJ.A. BaiG. StarrJ.T. WrightS.W. BusseniusJ. TanS. GopalsamyA. LefkerB.A. VincentF. JonesL.H. XuH. HothL.R. GeogheganK.F. QiuX. BunnageM.E. ThorarensenA. Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists.Sci. Rep.2016613085910.1038/srep30859 27527709
     [Google Scholar]
  41. SalentinS. SchreiberS. HauptV.J. AdasmeM.F. SchroederM. PLIP: fully automated protein–ligand interaction profiler.Nucleic Acids Res.201543W1W443W44710.1093/nar/gkv315 25873628
     [Google Scholar]
  42. DainaA. MichielinO. ZoeteV. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.Sci. Rep.2017714271710.1038/srep42717 28256516
     [Google Scholar]
  43. GudjonssonJ.E. JohnstonA. SigmundsdottirH. ValdimarssonH. Immunopathogenic mechanisms in psoriasis.Clin. Exp. Immunol.200313511810.1111/j.1365‑2249.2004.02310.x 14678257
     [Google Scholar]
  44. AricanO. AralM. SasmazS. CiragilP. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity.Mediators Inflamm.20052005527327910.1155/MI.2005.273 16258194
     [Google Scholar]
  45. LiY. ZhangG. ChenM. TongM. ZhaoM. TangF. XiaoR. WenH. Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice.Biomed. Pharmacother.20191091876188310.1016/j.biopha.2018.10.062 30551443
     [Google Scholar]
  46. BacchettiT. CampanatiA. FerrettiG. SimonettiO. LiberatiG. OffidaniA.M. Oxidative stress and psoriasis: The effect of antitumour necrosis factor-α inhibitor treatment.Br. J. Dermatol.2013168598498910.1111/bjd.12144 23614561
     [Google Scholar]
  47. AgarwalA. Aponte-MelladoA. PremkumarB.J. ShamanA. GuptaS. The effects of oxidative stress on female reproduction: A review.Reprod. Biol. Endocrinol.20121014910.1186/1477‑7827‑10‑49 22748101
     [Google Scholar]
  48. HsiehH.J. LiuC.A. HuangB. TsengA.H.H. WangD.L. Shear-induced endothelial mechanotransduction: The interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications.J. Biomed. Sci.2014211310.1186/1423‑0127‑21‑3 24410814
     [Google Scholar]
  49. HauteG.V. LuftC. AntunesG.L. SilveiraJ.S. Souza BassoB. CostaM.S. LevorseV.G.S. KaiberD.B. DonadioM.V.F. Gracia-SanchoJ. OliveiraJ.R. Anti‐inflammatory effect of octyl gallate in alveolar macrophages cells and mice with acute lung injury.J. Cell. Physiol.202023596073608410.1002/jcp.29536 31970778
     [Google Scholar]
  50. BosmanB. Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis.Skin Pharmacol. Physiol.19947632433410.1159/000211314 7946375
     [Google Scholar]
  51. IrreraN. BittoA. VaccaroM. ManninoF. SquadritoV. PallioG. ArcoraciV. MinutoliL. IeniA. LentiniM. AltavillaD. SquadritoF. PDRN, a bioactive natural compound, ameliorates imiquimod-induced psoriasis through NF-κB pathway inhibition and Wnt/β-Catenin signaling modulation.Int. J. Mol. Sci.2020214121510.3390/ijms21041215 32059361
     [Google Scholar]
  52. JacksonJ.M. TNF- α inhibitors.Dermatol. Ther.200720425126410.1111/j.1529‑8019.2007.00138.x 17970890
     [Google Scholar]
  53. IrreraN. VaccaroM. BittoA. PallioG. PizzinoG. LentiniM. ArcoraciV. MinutoliL. ScuruchiM. CutroneoG. AnastasiG.P. EttariR. SquadritoF. AltavillaD. BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis.Clin. Sci.2017131648749810.1042/CS20160645 28096316
     [Google Scholar]
  54. BustamiA. LestariW.P. HayuningrumC.F. WuyungP.E. WibowoH. NatadisastraR.M. The anti-inflammatory effect of octyl gallate through inhibition of nuclear factor-κB (NF-κB) pathway in rat endometriosis model.J. Reprod. Infertil.2020213169175 32685413
     [Google Scholar]
  55. HeY.Q. ZhouC.C. YuL.Y. WangL. DengJ. TaoY.L. ZhangF. ChenW.S. Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.Pharmacol. Res.202116310522410.1016/j.phrs.2020.105224 33007416
     [Google Scholar]
  56. IwataH. HagaN. UjiieH. Possible role of epiregulin from dermal fibroblasts in the keratinocyte hyperproliferation of psoriasis.J. Dermatol.20214891433143810.1111/1346‑8138.16003 34128258
     [Google Scholar]
  57. KruegerJ.G. WhartonK.A.Jr SchlittT. SuprunM. ToreneR.I. JiangX. WangC.Q. Fuentes-DuculanJ. HartmannN. PetersT. KorolevaI. HillenbrandR. LetzkusM. YuX. LiY. GlueckA. HasselbergA. FlanneryB. Suárez-FariñasM. HueberW. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.J. Allergy Clin. Immunol.2019144375076310.1016/j.jaci.2019.04.029 31129129
     [Google Scholar]
  58. AliZ. MatthewsR. Al-JanabiA. WarrenR.B. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.Expert Rev. Clin. Immunol.202117101073108110.1080/1744666X.2021.1967748 34384327
     [Google Scholar]
/content/journals/npj/10.2174/2210315513666230309141639
Loading
Octyl Gallate, a Potential Therapeutic Candidate for Psoriasis: An in vitro and in silico Anti-inflammatory Approach
Natural Products Journal, The 15, e090323214525 (2025); https://doi.org/10.2174/2210315513666230309141639
/content/journals/npj/10.2174/2210315513666230309141639
/content/journals/npj/10.2174/2210315513666230309141639
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): IL-17a; molecular docking; NO; octyl gallate; psoriasis; ROS; TNF-α

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test